Thank you for visiting our site! PharmaFarm desires to understand the business and development issues that influence the success of new pharmaceutical start-ups. We hope that by gaining a better understanding of these processes we can help future start-up companies more easily navigate the difficult road of ophthalmic pharmaceutical development.
Please visit other website pages to learn more about PharmaFarm research and services!
Stewart WC, Hernandez SM, Stewart JA, Nelson LA. Orphan Drug Designations in Ophthalmology. J Eye Dis Disord 2018;3:2(100117).
Stewart WC, Hernandez SM, Stewart JA, Nelson LA. Incidence of Ophthalmic Start-Ups. J Eye Dis Disord 2018;3:2(100119).
Stewart WC, Stewart JA, Nelson LA. Ophthalmic community perception of new medication needs. Int J Ophthalmol 2018;11:848-851.
Stewart WC, Nelson LA, Kruft B, Stewart JA. Ophthalmic start-up CEO’s perceptions of development hurdles. Ophthalmic Res 2018;59:110-4.
Stewart WC, Kruft B, Nelson LA, Stewart JA. Success of Ophthalmic Pharmaceutical Start-up Companies. Acta Ophthalmol 2018;96(2):266-8.
Stewart WC, Nelson LA, Eveleth DD. Endothelial Regeneration: Help Is on the Way. Review Ophthalmol 2015 Nov;74-80.
Stewart WC, Stewart JA, Nelson LA. How to assess an ophthalmic start-up. Review Ophthalmol 2015 Apr;62-69. http://www.reviewofophthalmology.com/content/i/3233/c/54164/
Stewart WC, Stewart JA, Nelson LA. First steps in creating a pharma start-up. Review Ophthalmol 2014 Apr;54-62. http://www.revophth.com/content/c/47509/
Stewart WC, Chaney PG, Stewart JA, Kruft B, Nelson LA. Qualitative factors underlying the successful investment in new ophthalmic pharmaceutical products in the United States. Acta Ophthalmol. 2013;91:496-497.
Stewart WC, Stewart JA, Nelson LA. The start-up: From dream to reality. Review Ophthalmol 2013;Apr:62-71. http://www.revophth.com/content/c/40144/
Stewart WC, Stewart JA, Kruft B, Nelson LA. Challenges facing ophthalmic startup companies in developing new devices or medicines. Acta Ophthalmol 2013;91 e81-83.